Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.97 USD | +1.14% | -7.22% | +146.75% |
05-28 | Johnson & Johnson Acquires Experimental Eczema Drug for $1.25 Billion | MT |
05-15 | Needham Adjusts Price Target on Arcutis Biotherapeutics to $18 From $16, Maintains Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+146.75% | 912M | |
+18.72% | 123B | |
+14.53% | 107B | |
-2.88% | 24.01B | |
+2.18% | 22.59B | |
-10.09% | 18.16B | |
-41.04% | 16.84B | |
-11.83% | 16.23B | |
+1.46% | 13.43B | |
+24.22% | 11.32B |
- Stock Market
- Equities
- ARQT Stock
- News Arcutis Biotherapeutics, Inc.
- Arcutis Biotherapeutics Shares Extend Decline Following Friday Announcement CFO Scott Burrows Leaving to 'Pursue External Opportunity'